Isaphar SRL
3.0 FTEThe score of Isaphar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -15 % Total assets +2 % Headcount (avg FTE) +11 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Isaphar's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −3,204 € | ||||
| Equity | 587,656 € | ||||
| Cash | 113,731 € | ||||
| EBITDA | 40,470 € | ||||
| Total assets | 928,025 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 17 Aug 2026
- Year ended 31 Dec 2024filed on 27 Jun 2025
- Year ended 31 Dec 2023filed on 09 Oct 2024
- Year ended 31 Dec 2022filed on 27 Sep 2023
- Year ended 31 Dec 2021filed on 29 Aug 2022
Isaphar's financial analysis
- Solvency63.3%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Isaphar
Isaphar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0870.744.254
- VAT number
- BE0870744254
- Peppol
- Registered · 0208:0870744254 · as of 09 Nov 2026
- Legal form
- SRL
- Incorporated
- 22 Dec 2004
- Registered office
- 7331 Saint-Ghislain
- Size
- Micro · 3.0 FTE
- Latest accounts
- 2025 · filed on 17 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Isaphar (SRL) has been based in Saint-Ghislain since 2004, active in: retail sale of pharmaceutical products. For 2025, it reports a net loss of 3,204 € and equity of 587,656 €; its revenue is not published. With 3.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 63.3%, above the median of its sector (41.5%).
Companies similar to Isaphar
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Vanackere Retail sale of pharmaceutical products Kortrijk · balance sheet 928,036 €
- Pharmacie MISSON Retail sale of pharmaceutical products Vielsalm · balance sheet 928,067 €
- Meurant Retail sale of pharmaceutical products Mons · balance sheet 928,752 €
- Apoteek VAN DER Sypt Retail sale of pharmaceutical products Beerse · balance sheet 929,004 €
- Bonte Retail sale of pharmaceutical products Waregem · balance sheet 929,758 €
- Farmacon Retail sale of pharmaceutical products Lokeren · balance sheet 929,902 €
- EL Rass Retail sale of pharmaceutical products Schaerbeek · balance sheet 925,904 €
- Pharma 4 Retail sale of pharmaceutical products Brussels · balance sheet 925,772 €
Frequently asked questions about Isaphar
What is the revenue of Isaphar?
Isaphar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Isaphar?
In Belgium, the VAT number is the company number prefixed with BE: BE0870744254 for Isaphar, if the company is VAT-registered. Its company number (CBE) is 0870.744.254.
Where is the registered office of Isaphar?
According to the CBE register, the registered office of Isaphar is in 7331 Saint-Ghislain.
What is the equity of Isaphar?
At the close of the 2025 financial year, the equity of Isaphar amounts to 587,656 €, a solvency of 63.3% of total assets.
How many people work at Isaphar?
3.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Isaphar?
The register lists 2 active mandates at Isaphar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Isaphar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →